#Dana-Farber Cancer Institute

Adding chemotherapy to Tagrisso was associated with a nearly nine-month delay in disease progression—and more side effects.

Dana-Farber researchers use artificial intelligence to efficiently diagnose muscle wasting in patients with head and neck cancers.

Overall survival was 14.4 months for HR+/HER2- patients who received sacituzumab govitecan versus 11.2 months for those given chemotherapy.

These individuals work to ensure fair opportunities to prevent, treat and survive cancer.

New research by Dana-Farber scientists looks at elevated body mass index and chemotherapy for acute lymphoblastic leukemia (ALL).

Researchers found a new way to detect cancer risk by looking for a signal in the blood, not for the presence of BRCA gene mutations.

The National Comprehensive Cancer Network (NCCN) developed a global roadmap for improving thyroid cancer care.

Vallurupalli, of Dana-Farber Cancer Institute, researches blood cancers and is passionate about equitable access to precision cancer care.

“Results of the POSITIVE trial confirm pregnancy can be a realistic objective for women who had an estrogen dependent breast cancer.”

New research from Dana-Farber Cancer Institute has identified 116 genes as key molecular vulnerabilities for multiple myeloma.

Researchers discover that specific gut bacteria can affect how well PD-1 checkpoint inhibitors work.

American Cancer Society and ACS Cancer Action Network strongly support Monica M. Bertagnolli, MD, as the next NIH director.

The American Cancer Society and ACS CAN applaud the pick. Bertagnolli, an oncologist, has been running the National Cancer Institute.

The National Comprehensive Cancer Network’s annual conference focused on better treatment, human connection and more. Here’s a roundup.

A group of proteins help activate cancer-fighting T cells and also trigger their exhaustion, find Dana Farber and NYU scientists.